Skip to content

Engineering the future of precision radio­therapeutics

Abdera is combining advanced antibody engineering with radiotherapeutics to attack cancer in bold new ways.


A custom-engineered approach to targeted radiotherapeutics

Our Platform

Abdera’s ROVEr™ platform integrates cutting-edge drug discovery and antibody engineering technologies to advance novel radiopharmaceutical-based cancer medicines with tunable PK properties focused on maximizing therapeutic effect while mitigating systemic toxicities.

Tunable precision cancer therapies

Abdera is building a pipeline of potential best-in-class radiotherapeutics capable of delivering alpha- or beta-emitting radionuclide payloads to a broad range of emerging and clinically validated solid tumor targets. Abdera plans to initiate a Phase 1 clinical trial of its lead program in of small cell lung cancer and large cell neuroendocrine carcinoma later this year.

Our Pipeline

Pioneers in radiotherapeutics

We are led by an exceptional team of scientists and company builders with demonstrated track records in drug development and expertise spanning oncology, radiotherapeutics and biologics.

Meet Our Team

Join us on our journey to develop better cancer treatments

Abdera is a fast-growing company looking for extraordinary individuals to join our team who want to make a difference in the lives of people living with cancer.

Join Us